Vandetanib is a protein tyrosine kinase inhibitor that has activity against the rearranged during transfection (RET) proto-oncogene. It also acts on both vascular and epidermal growth factor receptors, resulting in reduced endothelial cell migration, proliferation and survival, and reduced blood vessel formation in in vitro models of angiogenesis. Inhibition of angiogenesis has also been observed in mice and in MTC xenograph tumours in vivo; however, the precise mechanism of action in locally advanced or metastatic MTC is unknown.1
In a double-blind study (n=331), patients with advanced MTC were randomised to receive vandetanib (300mg daily) or placebo until disease progression, determined at regular intervals by central independent assessment using the Response Evaluation Criteria in Solid Tumours (RECIST). In the event of disease progression, patients had the option to receive open-label vandetanib.2
Overall, vandetanib significantly prolonged progression-free survival to a greater extent than placebo, with an average duration in the treatment arm of 30.5 months compared with 19.3 months in the control arm (hazard ratio 0.46; 95% CI, 0.31 to 0.69; p=0.0001).2
Adverse events were reported more frequently in patients who received vandetanib than in those who received placebo, with diarrhoea, rash, nausea, hypertension and headache occurring most commonly.1,2
1. Caprelsa Summary of Product Characteristics, February 2012.
2. Wells SA Jr et al. J Clin Oncol 2012; 10; 30: 134-41.
View Caprelsa drug record
Further information: AstraZeneca
Caprelsa: new option for advanced thyroid cancer
02 April 2012, 9:20am
Caprelsa (vandetanib) has been launched for the treatment of advanced medullary thyroid cancer (MTC) in unresectable locally advanced or metastatic disease.
Caprelsa may be less beneficial in patients with medullary thyroid carcinoma when rearranged during transfection (RET) mutation is negative or unknown | SCIENCE PHOTO LIBRARY
Related Drug Categories
Latest New Drugs News
- Pixuvri: new option in the treatment of non-Hodgkin's B-cell lymphoma
- Stivarga: a new oral multikinase inhibitor
- Imnovid: immunomodulator for multiple myeloma
- Erivedge: new skin cancer drug and first Hedgehog pathway inhibitor
- Iclusig: new protein kinase inhibitor for leukaemia
MIMS Specialist Journals
Now available on www.mims.co.uk
2-Part CME Diabetes Program
This activity will explore the latest data on the SGLT-2 inhibitors and implications for practice. Click here.
Access the full MIMS database from your mobile device
MIMs Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
Supplied by the National
Travel Health Network
and Centre (NaTHNaC)
Opioid dose conversions
and much more
Summary of routine
MIMS Summary of NHS Cancer Screening Referral Guidelines
Treatment regimens for common infections